<DOC>
	<DOCNO>NCT00763204</DOCNO>
	<brief_summary>The purpose study investigate dose-response relationship , antipsoriatic efficacy safety different concentration topical formulation AN2728 subject psoriasis vulgaris .</brief_summary>
	<brief_title>A Phase I Study Assess Novel Cream Psoriasis Plaque Test</brief_title>
	<detailed_description>The study perform 12 male subject stable psoriatic plaque . The study preparation comparator test observer-blind . Treatments randomly assign test field . All subject receive treatment , intraindividual comparison treatment . Altogether six test field examine per subject ( four active AN2728 cream different concentration : 2 % , 1 % , 0.3 % , 0.03 % , active ingredient-free vehicle , market corticoid preparation ) . The test field treat occlusively study period 12 day . Topical application approximately 200 uL assign intervention administer per treatment , total 10 treatment 12-day treatment period .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<criteria>male subject age 18 year old subject psoriasis vulgaris chronic stable phase stable plaque area sufficient five treatment field physical examination must without disease finding unless investigator considers abnormality irrelevant outcome study write informed consent obtain subject psoriasis guttata pustular psoriasis subject require systemically acting medication treatment psoriasis , might counter influence study objective , e.g . corticosteroid , cytostatics local treatment antipsoriatics ( like vitamin D , dithranol , glucocorticosteroids ; except salicyclic acid vaseline ) 4 week precede study ; antipsoriatic treatment plaque ( include corticosteroid , except salicyclic acid ) 8 week precede study . systemic treatment antipsoriatics three month precede study treatment systemic locally act medication might counter influence study aim ( e.g . MAO inhibitor , antiepileptic drug , antipsychotic drug ) medication know provoke aggravate psoriasis , e.g . Betablocker , antimalarial drug lithium drug within two week begin study study . know allergic reaction active ingredient component study preparation comparators blood pressure heart rate outside follow allow range : systolic blood pressure 80160 mm Hg , diastolic blood pressure 60 100 mm Hg , heart rate 40120 beats/min evidence drug abuse UVtherapy within 4 week begin study Symptoms clinically significant illness may influence outcome study 4 week study participation another clinical trial involve pharmaceutical product 4 week precede study opinion investigator physician perform initial examination patient participate study , e.g . due probable noncompliance inability understand study give adequately inform consent subject institutionalized legal regulatory order</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Plaque Type Psoriasis</keyword>
	<keyword>Topical</keyword>
</DOC>